Attentional Mechanisms in SCD

Recruiting now · Early Phase 1 · Has a placebo group

Conditions studied: Subjective Cognitive Decline

In brief

This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic function. The investigators anticipate that SCD will be associated with greater compensatory attention network activity and that disrupting this compensatory process through anticholinergic challenge will result in a greater negative effect on attentional performance (Attention Network Test, ANT) and attention network functioning (EEG) in older adults with greater subjective cognitive concern.

Key facts

Study ID

NCT06002477

Run by

Vanderbilt University Medical Center

People needed

80

Starts

2025-06-06

Expected to finish

2028-06-30

Last updated by the study team

2026-06-04

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• age ≥ 55
• Montreal Cognitive Assessment (MoCA) > 25 AND Global Deterioration Scale (GDS) rating < 3
• Non-smokers

You may not qualify if…

• medical contraindications to the drug challenge
• primary neurological disorder (such as stroke, epilepsy, etc.)

Where it is running

• Vanderbilt University Medical Center — Nashville, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.